Loading…

Metal ions, Alzheimer's disease and chelation therapy

In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegen...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmaceutica (Zagreb, Croatia) Croatia), 2011-03, Vol.61 (1), p.1-14
Main Author: Budimir, Ana
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673
cites cdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673
container_end_page 14
container_issue 1
container_start_page 1
container_title Acta pharmaceutica (Zagreb, Croatia)
container_volume 61
creator Budimir, Ana
description In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases. Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.
doi_str_mv 10.2478/v10007-011-0006-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_863899621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2928275231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</originalsourceid><addsrcrecordid>eNpdkE1LAzEQhoMoVqs_wIsseOjF1WTzfSzFWqEiSr30ErKbLN26HzXZFeuvN2VrD57mhXlmmHkAuELwLiFc3H8hCCGPIUJxCCxmR-AMCcJiSak4DhljGDqcDsC592sICeciOQWDBBHIMJZngD7bVpdR0dT-NhqXPytbVNaNfGQKb7W3ka5NlK1sqdvARO3KOr3ZXoCTXJfeXu7rELxPHxaTWTx_eXyajOdxRjht41QiklPJCZc0T2BKoabUaqJzYqSFmSGJSQVmUGc61yQRqTEC0VRwYThiHA_BqN-7cc1nZ32rqsJntix1bZvOK8GwkJIlKJA3_8h107k6HKcQRlJgnHAcKNRTmWu8dzZXG1dU2m0VgmqnVPVKVVCqdkoVCzPX-81dWllzmPhzGIC4Bwrf2u9DX7sPFV7gVL0uiHpD8xleLqeK4F9_9X50</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1319833273</pqid></control><display><type>article</type><title>Metal ions, Alzheimer's disease and chelation therapy</title><source>ProQuest - Publicly Available Content Database</source><creator>Budimir, Ana</creator><creatorcontrib>Budimir, Ana</creatorcontrib><description>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases. Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</description><identifier>ISSN: 1330-0075</identifier><identifier>EISSN: 1846-9558</identifier><identifier>DOI: 10.2478/v10007-011-0006-6</identifier><identifier>PMID: 21406339</identifier><language>eng</language><publisher>Croatia: Versita</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - physiopathology ; Alzheimer's disease ; Alzheimerova bolest ; Animals ; Chelating Agents - pharmacology ; chelation therapy ; Homeostasis - drug effects ; Humans ; Hydroxyquinolines - chemistry ; Hydroxyquinolines - pharmacology ; Ions - metabolism ; kelacijska terapija ; kovinski ioni ; kovinski kelatori ; metal chelators ; metal ions ; Metals - metabolism ; neurodegeneracija ; neurodegeneration ; Neurodegenerative Diseases - drug therapy ; Neurodegenerative Diseases - physiopathology</subject><ispartof>Acta pharmaceutica (Zagreb, Croatia), 2011-03, Vol.61 (1), p.1-14</ispartof><rights>Copyright Versita Mar 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</citedby><cites>FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1319833273?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21406339$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Budimir, Ana</creatorcontrib><title>Metal ions, Alzheimer's disease and chelation therapy</title><title>Acta pharmaceutica (Zagreb, Croatia)</title><addtitle>Acta Pharm</addtitle><description>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases. Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - physiopathology</subject><subject>Alzheimer's disease</subject><subject>Alzheimerova bolest</subject><subject>Animals</subject><subject>Chelating Agents - pharmacology</subject><subject>chelation therapy</subject><subject>Homeostasis - drug effects</subject><subject>Humans</subject><subject>Hydroxyquinolines - chemistry</subject><subject>Hydroxyquinolines - pharmacology</subject><subject>Ions - metabolism</subject><subject>kelacijska terapija</subject><subject>kovinski ioni</subject><subject>kovinski kelatori</subject><subject>metal chelators</subject><subject>metal ions</subject><subject>Metals - metabolism</subject><subject>neurodegeneracija</subject><subject>neurodegeneration</subject><subject>Neurodegenerative Diseases - drug therapy</subject><subject>Neurodegenerative Diseases - physiopathology</subject><issn>1330-0075</issn><issn>1846-9558</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkE1LAzEQhoMoVqs_wIsseOjF1WTzfSzFWqEiSr30ErKbLN26HzXZFeuvN2VrD57mhXlmmHkAuELwLiFc3H8hCCGPIUJxCCxmR-AMCcJiSak4DhljGDqcDsC592sICeciOQWDBBHIMJZngD7bVpdR0dT-NhqXPytbVNaNfGQKb7W3ka5NlK1sqdvARO3KOr3ZXoCTXJfeXu7rELxPHxaTWTx_eXyajOdxRjht41QiklPJCZc0T2BKoabUaqJzYqSFmSGJSQVmUGc61yQRqTEC0VRwYThiHA_BqN-7cc1nZ32rqsJntix1bZvOK8GwkJIlKJA3_8h107k6HKcQRlJgnHAcKNRTmWu8dzZXG1dU2m0VgmqnVPVKVVCqdkoVCzPX-81dWllzmPhzGIC4Bwrf2u9DX7sPFV7gVL0uiHpD8xleLqeK4F9_9X50</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Budimir, Ana</creator><general>Versita</general><general>De Gruyter Poland</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Metal ions, Alzheimer's disease and chelation therapy</title><author>Budimir, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - physiopathology</topic><topic>Alzheimer's disease</topic><topic>Alzheimerova bolest</topic><topic>Animals</topic><topic>Chelating Agents - pharmacology</topic><topic>chelation therapy</topic><topic>Homeostasis - drug effects</topic><topic>Humans</topic><topic>Hydroxyquinolines - chemistry</topic><topic>Hydroxyquinolines - pharmacology</topic><topic>Ions - metabolism</topic><topic>kelacijska terapija</topic><topic>kovinski ioni</topic><topic>kovinski kelatori</topic><topic>metal chelators</topic><topic>metal ions</topic><topic>Metals - metabolism</topic><topic>neurodegeneracija</topic><topic>neurodegeneration</topic><topic>Neurodegenerative Diseases - drug therapy</topic><topic>Neurodegenerative Diseases - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Budimir, Ana</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Acta pharmaceutica (Zagreb, Croatia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Budimir, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metal ions, Alzheimer's disease and chelation therapy</atitle><jtitle>Acta pharmaceutica (Zagreb, Croatia)</jtitle><addtitle>Acta Pharm</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>61</volume><issue>1</issue><spage>1</spage><epage>14</epage><pages>1-14</pages><issn>1330-0075</issn><eissn>1846-9558</eissn><abstract>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases. Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</abstract><cop>Croatia</cop><pub>Versita</pub><pmid>21406339</pmid><doi>10.2478/v10007-011-0006-6</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1330-0075
ispartof Acta pharmaceutica (Zagreb, Croatia), 2011-03, Vol.61 (1), p.1-14
issn 1330-0075
1846-9558
language eng
recordid cdi_proquest_miscellaneous_863899621
source ProQuest - Publicly Available Content Database
subjects Alzheimer Disease - drug therapy
Alzheimer Disease - physiopathology
Alzheimer's disease
Alzheimerova bolest
Animals
Chelating Agents - pharmacology
chelation therapy
Homeostasis - drug effects
Humans
Hydroxyquinolines - chemistry
Hydroxyquinolines - pharmacology
Ions - metabolism
kelacijska terapija
kovinski ioni
kovinski kelatori
metal chelators
metal ions
Metals - metabolism
neurodegeneracija
neurodegeneration
Neurodegenerative Diseases - drug therapy
Neurodegenerative Diseases - physiopathology
title Metal ions, Alzheimer's disease and chelation therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A47%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metal%20ions,%20Alzheimer's%20disease%20and%20chelation%20therapy&rft.jtitle=Acta%20pharmaceutica%20(Zagreb,%20Croatia)&rft.au=Budimir,%20Ana&rft.date=2011-03-01&rft.volume=61&rft.issue=1&rft.spage=1&rft.epage=14&rft.pages=1-14&rft.issn=1330-0075&rft.eissn=1846-9558&rft_id=info:doi/10.2478/v10007-011-0006-6&rft_dat=%3Cproquest_cross%3E2928275231%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1319833273&rft_id=info:pmid/21406339&rfr_iscdi=true